Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

New targeted drugs for metastatic renal cell carcinoma

ECCO 15 - ESMO 34

Published: 25 Sep 2009

Views: 12071

Rating:

Save

Dr Joaquim Bellmunt - Section Chief, Solid Tumor Oncology, Hospital del Mar, Barcelona, Spain

Expert interview with Dr Joaquim Bellmunt MD PhD conducted by Prof Gordon McVie

Categories:
Hepatobiliary pancreatic

Related Videos

Durvalumab plus bevacizumab, added to TACE, shows benefit for unresectable...

Dr Riccardo Lencioni - University of Pisa, Pisa, Italy

Durvalumab plus bevacizumab, added to TACE, shows benefit for unresectable hepatocellular carcinoma ( Dr Riccardo Lencioni - University of Pisa, Pisa, Italy )

Intra-arterial gemcitabine and IV gemcitabine/nab-paclitaxel show similar SAEs...

Dr Michael Pishvaian - Johns Hopkins Kimmel Cancer Center, Washington DC, USA

Intra-arterial gemcitabine and IV gemcitabine/nab-paclitaxel show similar SAEs in locally advanced pancreatic cancer ( Dr Michael Pishvaian - Johns Hopkins Kimmel Cancer Center, Washington DC, USA )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Next-generation selective RET inhibitor shows initial promise with RET-altered...

Prof Qing Zhou - Guangdong Provincial People’s Hospital, Guangzhou, China

Next-generation selective RET inhibitor shows initial promise with RET-altered solid tumours ( Prof Qing Zhou - Guangdong Provincial People’s Hospital, Guangzhou, China )

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses...

Dr Funda Meric-Bernstram - MD Anderson Cancer Center, Houston, USA

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses in multiple tumour types ( Dr Funda Meric-Bernstram - MD Anderson Cancer Center, Houston, USA )

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active...

Prof Masatoshi Kudo - Kindai University, Higashiōsaka, Japan

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL ( Prof Masatoshi Kudo - Kindai University, Higashiōsaka, Japan )

Durable effect of imatinib and metronomic chemotherapy with capecitabine in...

Dr Sana Al-Sukhun - Al Hyatt Oncology Practice, Amman, Jordan

Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma ( Dr Sana Al-Sukhun - Al Hyatt Oncology Practice, Amman, Jordan )

More from ecancer